According to the research report titled ‘North America Vascular Graft Market Forecast 2027 By Application, By Raw Material, By End-use, Research Report, Country Outlook, COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share’, available with Market Study Report, North America vascular graft market valuation is expected to reach USD 1 billion by the year 2027.
 

High prevalence of diabetes and other chronic diseases such as end-stage renal failure, rising geriatric population, along with increasing technological advancements are driving North America vascular graft market growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/4037683/
 

For the unversed, vascular surgery is a procedure that involves circumventing a constricted or blocked artery to restore blood flow to an extremity or an affected organ. A natural or synthetic graft is used to connect the constricted artery to a healthy one beyond the blockage site to create an alternate route for blood flow.
 

Despite the positive outlook, infections associated with the use of vascular grafts are likely to impede market development over the upcoming years.
 

Based on application type, North America vascular graft industry is arrayed into endovascular aneurysm repair (abdominal aortic aneurysms repair, thoracic aortic aneurysm repair), peripheral vascular repair, and hemodialysis access. Endovascular aneurysm repair segment accounted for USD 295.9 million of the total market revenue in 2020 as it is a cost-effective treatment option for patients suffering from abdominal aortic aneurysms.
 

As per raw material, the market is split into polyester grafts, polyurethane grafts, EPTFE grafts, and biosynthetic grafts. Of these, polyester grafts segment is estimated to be worth USD 646.4 million by 2027, owing to their use in treatment of a variety of conditions, including peripheral artery disease, thoracic and abdominal aortic aneurysms, and hemodialysis access.
 

Moving on to end user scope, the industry classification comprises ambulatory surgical centers, hospitals, and others. The hospital segment held 62% of North America vascular graft industry share in 2020, due to a notable increase in the number of minimally invasive surgeries, and supportive government laws promoting high-quality patient care in hospitals.
 

From a regional frame of reference, Canada industry is touted to register 5.7% CAGR through 2027. More than 45% of the Canadian population suffers from either high LDL cholesterol, blood pressure or smoking, putting them at a high risk of heart attack. Thus, increasing burden of cardiovascular illnesses has encourage major companies to expand their product & service portfolios, which is boosting the regional industry growth.
 

Prominent players in North America vascular graft industry sphere are CryoLife Inc., Endologix LLC, W. L. Gore & Associates Inc., Terumo Corp., Medtronic plc, LeMaitre Vascular Inc., Getinge AB, Cook Medical LLC, B. Braun Melsungen AG, and C. R. Bard Inc.